

Volume 1.13: June 12, 2017

Articles Events

Jobs

Subscribe

Publications of the Week

Selective Targeting and Therapy of Metastatic and Multidrug Resistant Tumours Using a Long Circulating Podophyllotoxin Nanoparticle

Roy, A. and Li, S.D., et al. | Biomaterials | UBC



Treatment options for metastatic and multidrug resistant (MDR) tumours are limited, and most of the chemotherapeutic drugs exhibit low efficacy against MDR cancers. An anti-tubulin agent, podophyllotoxin (PPT), displays high potency against MDR tumour cells. However, due to its poor solubility and non-specificity, PPT cannot be used systemically. The authors have developed a self-assembling nanoparticle dosage form for PPT that is effective against metastatic and MDR tumours. **Profile | Abstract**

REVIEW: Modelling the Process of Human Tumorigenesis

Balani, S. and Eaves, C.J., et al. | Nature Communications | BC Cancer Agency



Modelling the genesis of human cancers is at a scientific turning point. Starting from primary sources of normal human cells, it is now possible to reproducibly generate several types of malignant cell populations. The authors survey the advantages, contributions and limitations of current *de novo* human tumorigenesis strategies and note several exciting prospects on the horizon. **Abstract**

View All Publications 📀

Awards

Terry Thomas of STEMCELL Technologies Awarded the 2017 YWCA Woman of Distinction Award in Research & the Sciences

YWCA Vancouver




Terry Thomas is a creative, critical thinker who has dedicated her career to inventing technologies for the advancement of stem cell, regenerative medicine and cancer research. As the first scientist hired at STEMCELL Technologies Inc. in 1994, Terry has been seminal in building Canada's largest biotech company. She is an exceptional leader of young scientists, who has guided more than 135 PhD graduates to become senior managers in technology development. Read More

Local News

Canada 150: Dr. Victor Ling Made a Huge Breakthrough in Fighting Drug-Resistant Cancers

The Vancouver Sun



Victor Ling is considered one of the world's top cancer researchers. His titles have included director of cancer research at Vancouver Hospital and vice-president of research at the BC Cancer Agency. He is the now president and scientific director of the Terry Fox Research Institute. His ongoing research looks at resistance to anticancer drugs, with a focus on P-glycoprotein, which functions as a drug efflex pump of broad specificity. **Read More**

CBR Researchers Achieve near Atomic Resolution of *Salmonella*'s Nano-Syringe

The Centre for Blood Research (UBC)



How do pathogenic bacteria manipulate host cells and cause disease? What molecular structures allow them to accomplish such feats? Dr. Natalie Strynadka's laboratory and colleagues used cryo-electron microscopy to visualize molecular details of the "nano-syringe" *Salmonella* uses to inject virulence proteins into eukaryotic host cells and cause disease. **Read More**

Starving Research Means Less Crucial Innovation: Scientists

The Globe and Mail



"If there is one thing we have to keep doing, it is explaining and making the case for research – of all types: basic and applied," says David Naylor, author of the Naylor Report, or Canada's Fundamental Science Review, a government white paper that reviewed Canada's research apparatus and how to strengthen its flagging stature and output. **Read More**

Aequus Pharmaceuticals & CDRD Announce Research Collaboration to Improve Cannabinoid-Based Therapeutics

The Centre for Drug Research and Development



Aequus Pharmaceuticals, a specialty pharmaceutical company with expertise in drug delivery and clinical development, and the Centre For Drug Research and Development (CDRD), have announced a broad research collaboration to establish pre-clinical safety and efficacy of select cannabinoid-based therapeutics targeting neurological movement disorders including epilepsy, multiple sclerosis, Parkinson's disease and Huntington's disease. **Read More**

Orkla, Renaissance Ink Acrylamide-Reducing Yeast Deal

Sosland Publishing Company



Orkla Food Ingredients has signed a license agreement with Vancouver's Renaissance BioScience under which Orkla will produce and sell Renaissance acrylamide-reducing yeast to food manufacturers in the European Nordic and Baltic markets. The acrylamide-reducing yeast is patent pending and was developed using classical non-G.M.O. techniques. **Read More**

View All Articles 📀 | Submit an Article 📀

Count Colonies with Confidence: Attend Our CFU Assay Course

Join us in Vancouver, CA, Cambridge, UK or Dresden, DE

STEMCELL

Register Now



Ե Upcoming Events in Vancouver

- June 11 13 **Personalized Medicine Summit** Life Sciences Institute, UBC
- June 13 LifeSciences BC Salmon BBQ Cecil Green Park House
- June 16 Frontiers in Biophysics Life Sciences Institute, UBC
- June 23 D.R.I.N.K.S. Mahony and Sons, Stamps Landing
- June 27 Cafe Scientifique Fairview Pub

View All Events 📀 | Submit an Event 📀

Science Jobs in Vancouver

Scientific Inside Sales Representative STEMCELL Technologies Inc.

Research Associate

STEMCELL Technologies Inc.

Research Associate

Centre for Heart Lung Innovation, UBC

Postdoctoral Fellow

International Collaboration on Repair Discoveries, UBC

Clinical Research Coordinator

Providence Health Care Research Institute

